We are proud to accompany the CASMU hemotherapy service in the incorporation of technology to obtain safer blood components from the system INTERCEPT.
The system developed by CERUS It allows the inactivation of pathogens such as viruses, bacteria and parasites (known and emerging) as well as the remaining leukocytes.
In this way, patients (especially those who are immunocompromised) are protected from transfusion infections and transfusion-associated graft-versus-host disease, which also have a high cost for the health system.
